ABBV/(ENTA) had a 51%* worldwide share of 1Q19 combined ABBV/GILD HCV sales (#msg-148427663, #msg-148585355). The combined sales were flat QoQ (1605M/1600M).
*$815/$1,605M.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”